GeneVentiv Therapeutics

About:

GeneVentiv Therapeutics is a pre-clinical gene therapy company focused on blood diseases and disorders.

Top Investors: National Heart, Lung and Blood Institute, Innovate Carolina

Description:

GeneVentiv Therapeutics is a pre-clinical gene therapy company focused on blood diseases and disorders. With or without inhibitors, its flagship program, GENV-HEM, is the first universal gene therapy treatment for hemophilias A and B. The National Hemophilia Foundation has written a letter of support for GENV-HEM and the FDA has designated it as an orphan drug. A further gene therapy is being developed by GeneVentiv for Hemophilia Arthropathy, a degenerative joint disease that affects about 50% of hemophilia patients.

Total Funding Amount:

$3.95M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Raleigh, North Carolina, United States

Founded Date:

2020-01-01

Founders:

Number of Employees:

11-50

Last Funding Date:

2024-04-16

IPO Status:

Private

Industries: